EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study

Ling-Jen Hung, Ping-Chih Hsu, Cheng-Ta Yang, Chih-Hsi Scott Kuo, John Wen-Cheng Chang, Chen-Yang Huang, Ching-Fu Chang, Chiao-En Wu

Aging · 2024

DOI: 10.18632/aging.205395 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Aging, 2024. Verfasst von Ling-Jen Hung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Ta…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In real-world practice, most patients with lung cancer are diagnosed when they are aged ≥65 years. However, clinical trials tend to lack data for the elderly population. Therefore, we aimed to describe the effectiveness and safety of afatinib, gefitinib, and erlotinib for elderly patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC). METHODS: Treatment-naïve patients with EGFR-mutated advanced NSCLC were enrolled at many hospitals in Taiwan. Patient characteristics and the effectiveness and safety of afatinib, gefitinib, and erlotinib were compared. RESULTS: This study enrolled 1,343 treatment-naïve patients with EGFR-mutated advanced NSCLC, of whom 554 were aged

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedHumansAfatinibErbB ReceptorsErlotinib HydrochlorideGefitinibMutationProtein Kinase InhibitorsRetrospective Studies

Stichwörter der Autor:innen

elderly patientsepidermal growth factor receptornon-small-cell lung cancerreal-world evidencetyrosine kinase inhibitor

Substanzen

AfatinibErbB ReceptorsErlotinib HydrochlorideGefitinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 330, Taiwan.
  • Division of Thoracic Oncology, Department of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.

Zitieren

APA

Hung, L. J., Hsu, P. C., Yang, C. T., Kuo, C. S., Chang, J. W., Huang, C. Y., Chang, C. F., & Wu, C. E. (2024). Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study. Aging. https://doi.org/10.18632/aging.205395

Vancouver

Hung LJ, Hsu PC, Yang CT, Kuo CS, Chang JW, Huang CY, et al. Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study. Aging. 2024. doi:10.18632/aging.205395

BibTeX
@article{Hung2024,
  author = {Hung, Ling-Jen and Hsu, Ping-Chih and Yang, Cheng-Ta and Kuo, Chih-Hsi Scott and Chang, John Wen-Cheng and Huang, Chen-Yang and Chang, Ching-Fu and Wu, Chiao-En},
  title = {Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.205395}
}
Kostenlos starten →